Please login to the form below

Not currently logged in

Bedrock Group rebrands as Resonant Group

The rebrand reflects a new direction for the organisation, ten years after it was originally founded

Medical communications organisation Bedrock Group has announced that it will rebrand as Resonant Group, ten years after it was originally founded.

The rebrand reflects a new direction for the organisation as part of its growth plans and ambition to add other disciplines and services to its roster.

Currently, the group includes Origins Insights – a health insights agency – and Bedrock Healthcare Communications, which has a ‘forward-thinking, audience-centred, creative approach to medical communications’.

Both Origins Insights and Bedrock Healthcare Communications will keep their company names and identities, becoming the first two companies within the Resonant Group.

“Over the past decade, our business has developed significantly to serve the increasingly complex pharmaceutical and biotech industry. Rebranding as Resonant Group reflects our objective to provide the best, most impactful communication solutions for tomorrow’s world,” said David Youds (pictured above), founder and chief executive officer of Resonant Group.

“There’s never been a better time to be an independent agency group. Free of the constraints which bind so many network agencies, we are perfectly placed to evolve and enhance services, with client experience front of mind,” he added.

Article by
Lucy Parsons

6th April 2021

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....